

FORM PTO-1449  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. NEREUS.069A	APPLICATION NO. 10/673,038
	APPLICANT Mitchell, et al.	
	FILING DATE September 25, 2003	GROUP Unknown 1624

## **U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
J.K.	1. WO 99/07692	02/18/99	PCT				
J.K.	2. WO 00/37473	06/29/00	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
J.K.	3. Arai, et al. "Absolute Stereochemistry of Vicenistatin, a Novel 20-Membered Macrocyclic Lactam Antitumor Antibiotic." <i>Tetrahedron Letters.</i> 39: 3181-3184 (1998).
J.K.	International Search Report for International Application No. PCT/US 03/30518 dated 5/25/04

S:\DOCS\MTM\MTM-6572.DOC sma072204

EXAMINER <i>Dunk Kiff</i>	DATE CONSIDERED <i>4/12/06</i>
---------------------------	--------------------------------

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. NEREUS.069A	APPLICATION NO. 10/673,038
O P E J E T S INFORMATION DISCLOSURE STATEMENT BY APPLICANT SEP 15 2004 (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Mitchell, et al.	
		FILING DATE September 25, 2003	GROUP 1624



U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
JK	1	Aim, et al. "Effects of topically Applied PGF <sub>2α</sub> and its Isopropylester on Normal and Glaucomatous Human Eyes." <i>Prog. Clin. Biol. Res.</i> 312: 447-58 (1998).					
	2	"Bioreversible Carriers in Drug Design: Theory and Application," edited by E. B. Roche, Pergamon Press: New York, 14-21 (1987).					
	3	Fenical, William. "Chemical Studies of Marine Bacteria: Developing a New Resource." <i>Chem. Rev.</i> 93:1673-1683 (1993).					
	4	Fingl, et al. <i>Basis of Therapeutics</i> . 5 <sup>th</sup> Edition. Macmillan Publishing Co. Chp. 13. "Drugs Effective in the Therapy of the Epilepsies," (1975).					
	5	Fingl, et al. <i>Basis of Therapeutics</i> . 5 <sup>th</sup> Edition. Macmillan Publishing Co. Chp. 17. "Analgesic-Antipyretics, Anti-Inflammatory Agents, and Drugs Employed in the Therapy of Gout," (1975).					
	6	Fingl, Edward. <i>Basis of Therapeutics</i> . 5 <sup>th</sup> Edition. Macmillan Publishing Co. Chp. 49. "Laxatives and Cathartics," (1975).					
	7	Higuchi, et al. "Pro-drugs as Novel Delivery Systems." <i>A.C.S. Symposium Series</i> , American Chemical Society. 14(3): 154-183 (1975).					
	8	Joshi, A. "Microparticulates for Ophthalmic Drug Delivery." <i>J. Ocul. Pharmacol.</i> , 10(1):29-45 (1994).					
	9	Khokhlova, et al. "A Chemical Study of the Major Vitamycin Component." Institute of Microbiology, Academy of Sciences of the USSR, Moscow, pgs. 841-845, Russian (1964).					
	10	Krassilnikov, et al. "A New Species in the Group of <i>Actinomyces Aurantiacus</i> ," pgs. 482-489 (1960).					
	11	Mayer et al. "Efficacy of a Novel Hydrogel Formulation in Human Volunteers." <i>Ophthalmologica</i> . 210(2):101-3 (1996).					
	12	Mordenti, et al. "Intraocular Pharmacokinetics and Safety of a Humanized Monoclonal Antibody in Rabbits after Intravitreal Administration of a Solution or a PLGA Microsphere Formulation." <i>Toxicol. Sci.</i> 52(1):101-6 (1999).					
↓	13	Shedden, et al. "Efficacy and Tolerability of Timolol Maleate Ophthalmic Gel-Forming Solution Versus Timolol Ophthalmic Solution in Adults with Open-Angle Glaucoma or Ocular Hypertension: A Six-Month, Double-Masked, Multicenter Study." <i>Clin. Ther.</i> , 23(3): 440-50 (2001).					

S:\DOCS\MTMM\MTM-6823.DOC sma090204

EXAMINER	<i>David Kiff</i>	DATE CONSIDERED	4/2/06
*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			